Drugs that contain Paroxetine Mesylate

1. List of Brisdelle drug patents

BRISDELLE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(2 years from now)

US8946251 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(3 years from now)

US8658663 SEBELA IRELAND LTD Method of treating thermoregulatory disfunction with paroxetine
Apr, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(3 years from now)

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

How can I launch a generic of BRISDELLE before it's patent expiration?
More Information on Dosage

BRISDELLE family patents

8

United States

3

Korea, Republic of

2

Denmark

2

Slovenia

2

Lithuania

2

Hungary

2

Croatia

2

Portugal

2

Cyprus

2

Spain

2

Poland

2

RS

2

Japan

2

European Union

1

Israel

1

Mexico

1

Australia

1

Russia

1

Norway

1

Singapore

1

Brazil

1

China

1

Ukraine

1

Canada

1

New Zealand

1

ME

2. List of Pexeva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(2 years from now)

Market Authorisation Date: 03 July, 2003

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic